Nanome, a VR platform, assists scientists in understanding molecules in an enhanced manner which would ultimately aid in the future development of drugs.
One of the oldest and well-known applications of virtual reality is 3D visualization. A VR headset allows the user to visualize and study product designs in 3D prior to them going into production. The technology can also be used to showcase data sets in three dimensions that would assist researchers, analysts, and data scientists in recognizing complex relationships between data sets.
As it continues to offer something new and niche in terms of VR collaboration and visualization tools, Nanome, just announced a successful funding round that brought $3 million into the startup.
Bullpen Capital led the round which also saw participation from Oculus co-founder Michael Antonov’s Formic Adventures as well several other angel investors. The funds will be used to expand the VR startup’s team and foster new partnerships.
As per CEO Steve McCloskey, his company has a “compelling vision about what scientific collaboration should look like” and its platform is built with a mission to equip scientists working in several fields such as disease control, climate change, or anything else that is enhancing people’s lives.
The platform simplifies communication by uniting the scientists in a common virtual space to allow for seamless collaboration on complex molecules. This could drastically bring down the cost of drug development along with a host of other applications.
McCloskey came up with the idea for the concept while he was enrolled at UC San Diego where he was studying nano-engineering. What started as a visualization tool has now grown into a collaboration platform for chemists and biologists.
Nanome has licensing structures in place for academic and commercial uses. The platform, however, is free for personal use on HTC Vive, Oculus Rift, and, Valve Index headsets.
Follow us on LinkedIn
Read other Articles
